Cyclin-dependent kinase 12 (CDK12) phosphorylates the C-terminal domain of RNA polymerase II and is needed for the optimal transcription elongation and translation of a subset of human protein-coding genes. The kinase has a pleiotropic effect on the maintenance of genome stability, and its inactivation in prostate and ovarian tumours results in focal tandem duplications, a CDK12-unique genome instability phenotype. CDK12 aberrations were found in many other malignancies and have the potential to be used as biomarkers for therapeutic intervention. Moreover, the inhibition of CDK12 emerges as a promising strategy for treatment in several types of cancers. In this review, we summarize mechanisms that CDK12 utilizes for the regulation of gene expression and discuss how the perturbation of CDK12-sensitive genes contributes to the disruption of cell cycle progression and the onset of genome instability. Furthermore, we describe tumour-suppressive and oncogenic functions of CDK12 and its potential as a biomarker and inhibition target in anti-tumour treatments.

Central European Institute of Technology Masaryk University 62500 Brno Czech Republic

Zobrazit více v PubMed

Ko  T.K., Kelly E., Pines J.  CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J. Cell Sci. 2001; 114:2591–2603. PubMed

Edwards  M.C., Wong C., Elledge S.J.  Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity. Mol. Cell. Biol. 1998; 18:4291–4300. PubMed PMC

Bartkowiak  B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J., Price D.H., Adelman K., Lis J.T., Greenleaf A.L.  CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 2010; 24:2303–2316. PubMed PMC

Cancer Genome Atlas Research Network  Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609–615. PubMed PMC

Blazek  D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P., Luo Z., Cimermancic P., Ule J., Peterlin B.M.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011; 25:2158–2172. PubMed PMC

Kohoutek  J., Blazek D.  Cyclin K goes with Cdk12 and Cdk13. Cell Div. 2012; 7:12. PubMed PMC

Bosken  C.A., Farnung L., Hintermair C., Merzel Schachter M., Vogel-Bachmayr K., Blazek D., Anand K., Fisher R.P., Eick D., Geyer M.  The structure and substrate specificity of human Cdk12/Cyclin K. Nat. Commun. 2014; 5:3505. PubMed PMC

Greifenberg  A.K., Honig D., Pilarova K., Duster R., Bartholomeeusen K., Bosken C.A., Anand K., Blazek D., Geyer M.  Structural and functional analysis of the Cdk13/Cyclin K complex. Cell Rep. 2016; 14:320–331. PubMed

Dixon-Clarke  S.E., Elkins J.M., Cheng S.W., Morin G.B., Bullock A.N.  Structures of the CDK12/CycK complex with AMP-PNP reveal a flexible C-terminal kinase extension important for ATP binding. Sci. Rep. 2015; 5:17122. PubMed PMC

Ekumi  K.M., Paculova H., Lenasi T., Pospichalova V., Bosken C.A., Rybarikova J., Bryja V., Geyer M., Blazek D., Barboric M.  Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 2015; 43:2575–2589. PubMed PMC

Cheng  S.W., Kuzyk M.A., Moradian A., Ichu T.A., Chang V.C., Tien J.F., Vollett S.E., Griffith M., Marra M.A., Morin G.B.  Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol. Cell. Biol. 2012; 32:4691–4704. PubMed PMC

Dai  Q., Lei T., Zhao C., Zhong J., Tang Y.Z., Chen B., Yang J., Li C., Wang S., Song X.et al. .  Cyclin K-containing kinase complexes maintain self-renewal in murine embryonic stem cells. J. Biol. Chem. 2012; 287:25344–25352. PubMed PMC

Liang  K., Gao X., Gilmore J.M., Florens L., Washburn M.P., Smith E., Shilatifard A.  Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol. Cell. Biol. 2015; 35:928–938. PubMed PMC

Juan  H.C., Lin Y., Chen H.R., Fann M.J.  Cdk12 is essential for embryonic development and the maintenance of genomic stability. Cell Death Differ. 2015; 23:1038–1048. PubMed PMC

Fuda  N.J., Ardehali M.B., Lis J.T.  Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature. 2009; 461:186–192. PubMed PMC

Proudfoot  N.J.  Transcriptional termination in mammals: stopping the RNA polymerase II juggernaut. Science. 2016; 352:aad9926. PubMed PMC

Adelman  K., Lis J.T.  Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nat. Rev. Genet. 2012; 13:720–731. PubMed PMC

Core  L., Adelman K.  Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation. Genes Dev. 2019; 33:960–982. PubMed PMC

Harlen  K.M., Churchman L.S.  The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain. Nat. Rev. Mol. Cell Biol. 2017; 18:263–273. PubMed

Eick  D., Geyer M.  The RNA polymerase II carboxy-terminal domain (CTD) code. Chem. Rev. 2013; 113:8456–8490. PubMed

Zaborowska  J., Egloff S., Murphy S.  The pol II CTD: new twists in the tail. Nat. Struct. Mol. Biol. 2016; 23:771–777. PubMed

Herzel  L., Ottoz D.S.M., Alpert T., Neugebauer K.M.  Splicing and transcription touch base: co-transcriptional spliceosome assembly and function. Nat. Rev. Mol. Cell Biol. 2017; 18:637–650. PubMed PMC

Bentley  D.L.  Coupling mRNA processing with transcription in time and space. Nat. Rev. Genet. 2014; 15:163–175. PubMed PMC

Hsin  J.P., Manley J.L.  The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 2012; 26:2119–2137. PubMed PMC

Buratowski  S.  The CTD code. Nat. Struct. Biol. 2003; 10:679–680. PubMed

Chapman  R.D., Heidemann M., Albert T.K., Mailhammer R., Flatley A., Meisterernst M., Kremmer E., Eick D.  Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science. 2007; 318:1780–1782. PubMed

Buratowski  S.  Progression through the RNA polymerase II CTD cycle. Mol. Cell. 2009; 36:541–546. PubMed PMC

Qiu  H., Hu C., Hinnebusch A.G.  Phosphorylation of the Pol II CTD by KIN28 enhances BUR1/BUR2 recruitment and Ser2 CTD phosphorylation near promoters. Mol. Cell. 2009; 33:752–762. PubMed PMC

Booth  G.T., Parua P.K., Sanso M., Fisher R.P., Lis J.T.  Cdk9 regulates a promoter-proximal checkpoint to modulate RNA polymerase II elongation rate in fission yeast. Nat. Commun. 2018; 9:543. PubMed PMC

Coudreuse  D., van Bakel H., Dewez M., Soutourina J., Parnell T., Vandenhaute J., Cairns B., Werner M., Hermand D.  A gene-specific requirement of RNA polymerase II CTD phosphorylation for sexual differentiation in S. pombe. Curr. Biol. 2010; 20:1053–1064. PubMed

Bowman  E.A., Bowman C.R., Ahn J.H., Kelly W.G.  Phosphorylation of RNA polymerase II is independent of P-TEFb in the C. elegans germline. Development. 2013; 140:3703–3713. PubMed PMC

Peterlin  B.M., Price D.H.  Controlling the elongation phase of transcription with P-TEFb. Mol. Cell. 2006; 23:297–305. PubMed

Ebmeier  C.C., Erickson B., Allen B.L., Allen M.A., Kim H., Fong N., Jacobsen J.R., Liang K.W., Shilatifard A., Dowell R.D.et al. .  Human TFIIH kinase CDK7 regulates transcription-associated chromatin modifications. Cell Rep. 2017; 20:1173–1186. PubMed PMC

Devaiah  B.N., Lewis B.A., Cherman N., Hewitt M.C., Albrecht B.K., Robey P.G., Ozato K., Sims R.J., Singer D.S.  BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 2012; 109:6927–6932. PubMed PMC

Bartkowiak  B., Greenleaf A.L.  Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex. J. Biol. Chem. 2015; 290:1786–1795. PubMed PMC

Davidson  L., Muniz L., West S.  3′ end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells. Genes Dev. 2014; 28:342–356. PubMed PMC

Eifler  T.T., Shao W., Bartholomeeusen K., Fujinaga K., Jager S., Johnson J.R., Luo Z., Krogan N.J., Peterlin B.M.  Cyclin-dependent kinase 12 increases 3′ end processing of growth factor-induced c-FOS transcripts. Mol. Cell. Biol. 2015; 35:468–478. PubMed PMC

Zhang  T., Kwiatkowski N., Olson C.M., Dixon-Clarke S.E., Abraham B.J., Greifenberg A.K., Ficarro S.B., Elkins J.M., Liang Y., Hannett N.M.et al. .  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 2016; 12:876–884. PubMed PMC

Chirackal Manavalan  A.P., Pilarova K., Kluge M., Bartholomeeusen K., Rajecky M., Oppelt J., Khirsariya P., Paruch K., Krejci L., Friedel C.C.et al. .  CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Rep. 2019; 20:e47592. PubMed PMC

Krajewska  M., Dries R., Grassetti A.V., Dust S., Gao Y., Huang H., Sharma B., Day D.S., Kwiatkowski N., Pomaville M.et al. .  CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 2019; 10:1757. PubMed PMC

Bartkowiak  B., Yan C., Greenleaf A.L.  Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas. Biochim. Biophys. Acta. 2015; 1849:1179–1187. PubMed PMC

Quereda  V., Bayle S., Vena F., Frydman S.M., Monastyrskyi A., Roush W.R., Duckett D.R.  Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. Cancer Cell. 2019; 36:545–558. PubMed

Schuller  R., Forne I., Straub T., Schreieck A., Texier Y., Shah N., Decker T.M., Cramer P., Imhof A., Eick D.  Heptad-specific phosphorylation of RNA polymerase II CTD. Mol. Cell. 2016; 61:305–314. PubMed

Suh  H., Ficarro S.B., Kang U.B., Chun Y., Marto J.A., Buratowski S.  Direct analysis of phosphorylation sites on the Rpb1 C-terminal domain of RNA polymerase II. Mol. Cell. 2016; 61:297–304. PubMed PMC

Dubbury  S.J., Boutz P.L., Sharp P.A.  CDK12 regulates DNA repair genes by suppressing intronic polyadenylation. Nature. 2018; 564:141–145. PubMed PMC

Tien  J.F., Mazloomian A., Cheng S.G., Hughes C.S., Chow C.C.T., Canapi L.T., Oloumi A., Trigo-Gonzalez G., Bashashati A., Xu J.et al. .  CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Res. 2017; 45:6698–6716. PubMed PMC

Popova  T., Manie E., Boeva V., Battistella A., Goundiam O., Smith N.K., Mueller C.R., Raynal V., Mariani O., Sastre-Garau X.et al. .  Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 2016; 76:1882–1891. PubMed

Blazek  D.  Transcriptional kinases: caught by a sticky drug. Nat. Chem. Biol. 2016; 12:765–766. PubMed

Li  X., Chatterjee N., Spirohn K., Boutros M., Bohmann D.  Cdk12 is a gene-selective RNA polymerase II kinase that regulates a subset of the transcriptome, including Nrf2 target genes. Sci. Rep. 2016; 6:21455. PubMed PMC

Pan  L., Xie W., Li K.L., Yang Z., Xu J., Zhang W., Liu L.P., Ren X., He Z., Wu J.et al. .  Heterochromatin remodeling by CDK12 contributes to learning in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2015; 112:13988–13993. PubMed PMC

Gressel  S., Schwalb B., Decker T.M., Qin W., Leonhardt H., Eick D., Cramer P.  CDK9-dependent RNA polymerase II pausing controls transcription initiation. Elife. 2017; 6:e29736. PubMed PMC

Oh  J.M., Di C., Venters C.C., Guo J.N., Arai C., So B.R., Pinto A.M., Zhang Z.X., Wan L.L., Younis I.et al. .  U1 snRNP telescripting regulates a size-function-stratified human genome. Nat. Struct. Mol. Biol. 2017; 24:993–999. PubMed PMC

Kamieniarz-Gdula  K., Gdula M.R., Panser K., Nojima T., Monks J., Wisniewski J.R., Riepsaame J., Brockdorff N., Pauli A., Proudfoot N.J.  Selective roles of vertebrate PCF11 in premature and full-length transcript termination. Mol. Cell. 2019; 74:158–172. PubMed PMC

Gregersen  L.H., Mitter R., Ugalde A.P., Nojima T., Proudfoot N.J., Agami R., Stewart A., Svejstrup J.Q.  SCAF4 and SCAF8, mRNA anti-terminator proteins. Cell. 2019; 177:1797–1813. PubMed PMC

Yu  M., Yang W., Ni T., Tang Z., Nakadai T., Zhu J., Roeder R.G.  RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science. 2015; 350:1383–1386. PubMed PMC

Van Oss  S.B., Cucinotta C.E., Arndt K.M.  Emerging insights into the roles of the Paf1 complex in gene regulation. Trends Biochem. Sci. 2017; 42:788–798. PubMed PMC

Hou  L., Wang Y., Liu Y., Zhang N., Shamovsky I., Nudler E., Tian B., Dynlacht B.D.  Paf1C regulates RNA polymerase II progression by modulating elongation rate. Proc. Natl. Acad. Sci. U.S.A. 2019; 116:14583–14592. PubMed PMC

Fitz  J., Neumann T., Pavri R.  Regulation of RNA polymerase II processivity by Spt5 is restricted to a narrow window during elongation. EMBO J. 2018; 37:e97965. PubMed PMC

Shetty  A., Kallgren S.P., Demel C., Maier K.C., Spatt D., Alver B.H., Cramer P., Park P.J., Winston F.  Spt5 plays vital roles in the control of sense and antisense transcription elongation. Mol. Cell. 2017; 66:77–88. PubMed PMC

Hoshii  T., Cifani P., Feng Z., Huang C.H., Koche R., Chen C.W., Delaney C.D., Lowe S.W., Kentsis A., Armstrong S.A.  A non-catalytic function of SETD1A regulates cyclin K and the DNA damage response. Cell. 2018; 172:1007–1021. PubMed PMC

Eifler  T.T., Shao W., Bartholomeeusen K., Fujinaga K., Jager S., Johnson J., Luo Z., Krogan N., Peterlin B.M.  CDK12 increases 3′ end processing of growth factor-induced c-FOS transcripts. Mol. Cell. Biol. 2014; 35:468–478. PubMed PMC

Lin  X., Taube R., Fujinaga K., Peterlin B.M.  P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA. J. Biol. Chem. 2002; 277:16873–16878. PubMed

Chen  H.H., Wang Y.C., Fann M.J.  Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol. Cell. Biol. 2006; 26:2736–2745. PubMed PMC

Ghamari  A., van de Corput M.P., Thongjuea S., van Cappellen W.A., van Ijcken W., van Haren J., Soler E., Eick D., Lenhard B., Grosveld F.G.  In vivo live imaging of RNA polymerase II transcription factories in primary cells. Genes Dev. 2013; 27:767–777. PubMed PMC

Spector  D.L., Lamond A.I.  Nuclear speckles. Cold Spring Harb. Perspect. Biol. 2011; 3:a000646. PubMed PMC

Gu  B., Eick D., Bensaude O.  CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo. Nucleic Acids Res. 2013; 41:1591–1603. PubMed PMC

David  C.J., Boyne A.R., Millhouse S.R., Manley J.L.  The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65–Prp19 complex. Genes Dev. 2011; 25:972–983. PubMed PMC

Rodrigues  F., Thuma L., Klambt C.  The regulation of glial-specific splicing of Neurexin IV requires HOW and Cdk12 activity. Development. 2012; 139:1765–1776. PubMed

Drogat  J., Hermand D.  Gene-specific requirement of RNA polymerase II CTD phosphorylation. Mol. Microbiol. 2012; 84:995–1004. PubMed

Hurt  E., Luo M.J., Rother S., Reed R., Strasser K.  Cotranscriptional recruitment of the serine–arginine-rich (SR)-like proteins Gbp2 and Hrb1 to nascent mRNA via the TREX complex. Proc. Natl. Acad. Sci. U.S.A. 2004; 101:1858–1862. PubMed PMC

Cho  E.J., Kobor M.S., Kim M., Greenblatt J., Buratowski S.  Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. Genes Dev. 2001; 15:3319–3329. PubMed PMC

Ahn  S.H., Kim M., Buratowski S.  Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3′ end processing. Mol. Cell. 2004; 13:67–76. PubMed

Kim  H., Erickson B., Luo W., Seward D., Graber J.H., Pollock D.D., Megee P.C., Bentley D.L.  Gene-specific RNA polymerase II phosphorylation and the CTD code. Nat. Struct. Mol. Biol. 2010; 17:1279–1286. PubMed PMC

Choi  S.H., Martinez T.F., Kim S., Donaldson C., Shokhirev M.N., Saghatelian A., Jones K.A.  CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability. Genes Dev. 2019; 33:418–435. PubMed PMC

Rother  S., Strasser K.  The RNA polymerase II CTD kinase Ctk1 functions in translation elongation. Genes Dev. 2007; 21:1409–1421. PubMed PMC

Coordes  B., Brunger K.M., Burger K., Soufi B., Horenk J., Eick D., Olsen J.V., Strasser K.  Ctk1 function is necessary for full translation initiation activity in Saccharomyces cerevisiae. Eukaryot. Cell. 2015; 14:86–95. PubMed PMC

Xiang  X., Deng L., Zhang J., Zhang X., Lei T., Luan G., Yang C., Xiao Z.X., Li Q., Li Q.  A distinct expression pattern of cyclin K in mammalian testes suggests a functional role in spermatogenesis. PLoS One. 2014; 9:e101539. PubMed PMC

Lei  T., Zhang P., Zhang X., Xiao X., Zhang J., Qiu T., Dai Q., Zhang Y., Min L., Li Q.et al. .  Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation. Nat. Commun. 2018; 9:1876. PubMed PMC

Bracken  A.P., Ciro M., Cocito A., Helin K.  E2F target genes: unraveling the biology. Trends Biochem. Sci. 2004; 29:409–417. PubMed

Lobrich  M., Jeggo P.A.  The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer. 2007; 7:861–869. PubMed

Schecher  S., Walter B., Falkenstein M., Macher-Goeppinger S., Stenzel P., Krumpelmann K., Hadaschik B., Perner S., Kristiansen G., Duensing S.et al. .  Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer. Int. J. Cancer. 2017; 141:1643–1653. PubMed

Bajrami  I., Frankum J.R., Konde A., Miller R.E., Rehman F.L., Brough R., Campbell J., Sims D., Rafiq R., Hooper S.et al. .  Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 2014; 74:287–297. PubMed PMC

Joshi  P.M., Sutor S.L., Huntoon C.J., Karnitz L.M.  Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 2014; 289:9247–9253. PubMed PMC

Gaillard  H., Garcia-Muse T., Aguilera A.  Replication stress and cancer. Nat. Rev. Cancer. 2015; 15:276–289. PubMed

Zeman  M.K., Cimprich K.A.  Causes and consequences of replication stress. Nat. Cell Biol. 2014; 16:2–9. PubMed PMC

Lawrence  K.S., Chau T., Engebrecht J.  DNA damage response and spindle assembly checkpoint function throughout the cell cycle to ensure genomic integrity. PLoS Genet. 2015; 11:e1005150. PubMed PMC

Janssen  A., van der Burg M., Szuhai K., Kops G.J., Medema R.H.  Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science. 2011; 333:1895–1898. PubMed

Wu  Y.M., Cieslik M., Lonigro R.J., Vats P., Reimers M.A., Cao X., Ning Y., Wang L., Kunju L.P., de Sarkar N.et al. .  Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018; 173:1770–1782. PubMed PMC

Menghi  F., Barthel F.P., Yadav V., Tang M., Ji B., Tang Z., Carter G.W., Ruan Y., Scully R., Verhaak R.G.W.et al. .  The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations. Cancer Cell. 2018; 34:197–210. PubMed PMC

Quigley  D.A., Dang H.X., Zhao S.G., Lloyd P., Aggarwal R., Alumkal J.J., Foye A., Kothari V., Perry M.D., Bailey A.M.et al. .  Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018; 175:889. PubMed

Rao  M., Powers S.  Tandem duplications may supply the missing genetic alterations in many triple-negative breast and gynecological cancers. Cancer Cell. 2018; 34:179–180. PubMed

Menghi  F., Inaki K., Woo X., Kumar P.A., Grzeda K.R., Malhotra A., Yadav V., Kim H., Marquez E.J., Ucar D.et al. .  The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proc. Natl. Acad. Sci. U.S.A. 2016; 113:E2373–E2382. PubMed PMC

van Dessel  L.F., van Riet J., Smits M., Zhu Y., Hamberg P., van der Heijden M.S., Bergman A.M., van Oort I.M., de Wit R., Voest E.E.et al. .  The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat. Commun. 2019; 10:5251. PubMed PMC

Antonarakis  E.S.  Cyclin-dependent kinase 12, immunity, and prostate cancer. N. Engl. J. Med. 2018; 379:1087–1089. PubMed

Branzei  D., Szakal B.  Building up and breaking down: mechanisms controlling recombination during replication. Crit. Rev. Biochem. Mol. Biol. 2017; 52:381–394. PubMed

Sokol  E.S., Pavlick D., Frampton G.M., Ross J.S., Miller V.A., Ali S.M., Lotan T.L., Pardoll D.M., Chung J.H., Antonarakis E.S.  Pan-cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype. Oncologist. 2019; 24:1526–1533. PubMed PMC

Lui  G.Y.L., Grandori C., Kemp C.J.  CDK12: an emerging therapeutic target for cancer. J. Clin. Pathol. 2018; 71:957–962. PubMed PMC

Paculova  H., Kohoutek J.  The emerging roles of CDK12 in tumorigenesis. Cell Div. 2017; 12:7. PubMed PMC

Blazek  D.  The cyclin K/Cdk12 complex: an emerging new player in the maintenance of genome stability. Cell Cycle. 2012; 11:1049–1050. PubMed PMC

Carter  S.L., Cibulskis K., Helman E., McKenna A., Shen H., Zack T., Laird P.W., Onofrio R.C., Winckler W., Weir B.A.et al. .  Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 2012; 30:413–421. PubMed PMC

Bradner  J.E., Hnisz D., Young R.A.  Transcriptional addiction in cancer. Cell. 2017; 168:629–643. PubMed PMC

O’Connor  M.J.  Targeting the DNA damage response in cancer. Mol. Cell. 2015; 60:547–560. PubMed

Toyoshima  M., Howie H.L., Imakura M., Walsh R.M., Annis J.E., Chang A.N., Frazier J., Chau B.N., Loboda A., Linsley P.S.et al. .  Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc. Natl. Acad. Sci. U.S.A. 2012; 109:9545–9550. PubMed PMC

Delehouze  C., Godl K., Loaec N., Bruyere C., Desban N., Oumata N., Galons H., Roumeliotis T.I., Giannopoulou E.G., Grenet J.et al. .  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 2014; 33:5675–5687. PubMed PMC

Sircoulomb  F., Bekhouche I., Finetti P., Adelaide J., Ben Hamida A., Bonansea J., Raynaud S., Innocenti C., Charafe-Jauffret E., Tarpin C.et al. .  Genome profiling of ERBB2-amplified breast cancers. BMC Cancer. 2010; 10:539. PubMed PMC

Mertins  P., Mani D.R., Ruggles K.V., Gillette M.A., Clauser K.R., Wang P., Wang X., Qiao J.W., Cao S., Petralia F.et al. .  Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016; 534:55–62. PubMed PMC

Capra  M., Nuciforo P.G., Confalonieri S., Quarto M., Bianchi M., Nebuloni M., Boldorini R., Pallotti F., Viale G., Gishizky M.L.et al. .  Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res. 2006; 66:8147–8154. PubMed

Naidoo  K., Wai P.T., Maguire S.L., Daley F., Haider S., Kriplani D., Campbell J., Mirza H., Grigoriadis A., Tutt A.et al. .  Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response-targeted therapies in breast cancer. Mol. Cancer Ther. 2018; 17:306–315. PubMed PMC

Natrajan  R., Wilkerson P.M., Marchio C., Piscuoglio S., Ng C.K., Wai P., Lambros M.B., Samartzis E.P., Dedes K.J., Frankum J.et al. .  Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J. Pathol. 2014; 232:553–565. PubMed PMC

Choi  H.J., Jin S., Cho H., Won H.Y., An H.W., Jeong G.Y., Park Y.U., Kim H.Y., Park M.K., Son T.et al. .  CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1–ErbB–PI3K signaling. EMBO Rep. 2019; 20:e48058. PubMed PMC

Viswanathan  S.R., Ha G., Hoff A.M., Wala J.A., Carrot-Zhang J., Whelan C.W., Haradhvala N.J., Freeman S.S., Reed S.C., Rhoades J.et al. .  Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell. 2018; 174:433–447. PubMed PMC

Byrum  A.K., Vindigni A., Mosammaparast N.  Defining and modulating ‘BRCAness’. Trends Cell Biol. 2019; 29:740–751. PubMed

Lord  C.J., Ashworth A.  BRCAness revisited. Nat. Rev. Cancer. 2016; 16:110–120. PubMed

Lord  C.J., Ashworth A.  PARP inhibitors: synthetic lethality in the clinic. Science. 2017; 355:1152–1158. PubMed PMC

Staaf  J., Glodzik D., Bosch A., Vallon-Christersson J., Reutersward C., Hakkinen J., Degasperi A., Amarante T.D., Saal L.H., Hegardt C.et al. .  Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat. Med. 2019; 25:1526–1533. PubMed PMC

Johnson  S.F., Cruz C., Greifenberg A.K., Dust S., Stover D.G., Chi D., Primack B., Cao S., Bernhardy A.J., Coulson R.et al. .  CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016; 17:2367–2381. PubMed PMC

Bayles  I., Krajewska M., Pontius W.D., Saiakhova A., Morrow J.J., Bartels C., Lu J., Faber Z.J., Fedorov Y., Hong E.S.et al. .  Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J. Clin. Invest. 2019; 129:4377–4392. PubMed PMC

Drean  A., Lord C.J., Ashworth A.  PARP inhibitor combination therapy. Crit. Rev. Oncol. Hematol. 2016; 108:73–85. PubMed

Chung  J.H., Dewal N., Sokol E., Mathew P., Whitehead R., Millis S.Z., Frampton G.M., Bratslavsky G., Pal S.K., Lee R.J.et al. .  Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis. Oncol. 2019; 3:1–23. PubMed PMC

Mateo  J., Seed G., Bertan C., Rescigno P., Dolling D., Figueiredo I., Miranda S., Nava Rodrigues D., Gurel B., Clarke M.et al. .  Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 2019; 130:1558–8238. PubMed PMC

Reimers  M.A., Yip S.M., Zhang L., Cieslik M., Dhawan M., Montgomery B., Wyatt A.W., Chi K.N., Small E.J., Chinnaiyan A.M.et al. .  Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur. Urol. 2019; 77:333–341. PubMed PMC

Luo  J., Antonarakis E.S.  PARP inhibition—not all gene mutations are created equal. Nat. Rev. Urol. 2019; 16:4–6. PubMed PMC

Chen  H., Liu H.D., Qing G.L.  Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Target. Ther. 2018; 3:5. PubMed PMC

Zeng  M., Kwiatkowski N.P., Zhang T., Nabet B., Xu M., Liang Y., Quan C., Wang J., Hao M., Palakurthi S.et al. .  Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018; 7:e39030. PubMed PMC

Spector  N.L., Blackwell K.L.  Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2009; 27:5838–5847. PubMed

Wang  C., Wang H., Lieftink C., du Chatinier A., Gao D., Jin G., Jin H., Beijersbergen R.L., Qin W., Bernards R.  CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 2019; doi:10.1136/gutjnl-2019-318506. PubMed

Pishas  K.I., Lessnick S.L.  Recent advances in targeted therapy for Ewing sarcoma [version 1; peer review: 2 approved]. F1000Res. 2016; 5:2077. PubMed PMC

Iniguez  A.B., Stolte B., Wang E.J., Conway A.S., Alexe G., Dharia N.V., Kwiatkowski N., Zhang T.H., Abraham B.J., Mora J.et al. .  EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma. Cancer Cell. 2018; 33:202–216. PubMed PMC

Paculova  H., Kramara J., Simeckova S., Fedr R., Soucek K., Hylse O., Paruch K., Svoboda M., Mistrik M., Kohoutek J.  BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumour Biol. 2017; 39:1–11. PubMed

Le  D.T., Durham J.N., Smith K.N., Wang H., Bartlett B.R., Aulakh L.K., Lu S., Kemberling H., Wilt C., Luber B.S.et al. .  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357:409–413. PubMed PMC

Le  D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D.et al. .  PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015; 372:2509–2520. PubMed PMC

Antonarakis  E.S., Velho P.I., Agarwal N., Santos V.S., Maughan B.L., Pili R., Adra N., Sternberg C.N., Vlachostergios P.J., Tagawa S.T.et al. .  CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors. Ann. Oncol. 2019; 30:326–355.

Marshall  C.H., Imada E.L., Tang Z., Marchionni L., Antonarakis E.S.  CDK12 inactivation across solid tumors: an actionable genetic subtype. Oncoscience. 2019; 6:312–316. PubMed PMC

Zehir  A., Benayed R., Shah R.H., Syed A., Middha S., Kim H.R., Srinivasan P., Gao J., Chakravarty D., Devlin S.M.et al. .  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017; 23:703–713. PubMed PMC

Kanakkanthara  A., Kurmi K., Ekstrom T.L., Hou X., Purfeerst E.R., Heinzen E.P., Correia C., Huntoon C.J., O’Brien D., Wahner Hendrickson A.E.et al. .  BRCA1 deficiency upregulates NNMT, which reprograms metabolism and sensitizes ovarian cancer cells to mitochondrial metabolic targeting agents. Cancer Res. 2019; 79:5920–5929. PubMed PMC

Vander Heiden  M.G.  Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011; 10:671–684. PubMed

Early embryogenesis in CHDFIDD mouse model reveals facial clefts and altered cranial neurogenesis

CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells